Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$41.99 USD
-0.53 (-1.25%)
Updated May 10, 2024 04:00 PM ET
After-Market: $42.00 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
APLS 41.99 -0.53(-1.25%)
Will APLS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLS
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
Other News for APLS
Strong Performance and Growth Potential Affirm Buy Rating for Apellis Pharmaceuticals
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
Apellis stock sell-off over Syfovre sales "overdone," says Citi
Apellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive Pressures
Wall Street Analysts Are Bullish on Top Healthcare Picks